Piper Sandler lowered the firm’s price target on Prothena (PRTA) to $81 from $110 and keeps an Overweight rating on the shares. The firm was disappointed to see Phase 3 AFFIRM-AL miss statistical significance on its primary and secondary endpoints despite initially being bullish on its potential. Consequently, Prothena will no longer pursue this asset, thus Piper removed birtamimab in AL amyloidosis from its model.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRTA:
- Prothena’s Strategic Shift and Promising Alzheimer’s Pipeline Drive Buy Rating
- Prothena price target lowered to $14 from $30 at H.C. Wainwright
- Prothena price target lowered to $29 from $78 at Citizens JMP
- Prothena price target lowered to $18 from $40 at Chardan
- Prothena downgraded to Hold from Buy at Jefferies
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue